Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Eccogene logo — Unlocking the full potential of GLP-1-based therapy

Eccogene

Unlocking the full potential of GLP-1-based therapy

Founded 2018 United States Cambridge, United States 32 employees Series B Total: $194.63M Health Care

General Information

Company Name Eccogene
Founded Year 2018
Location United States Cambridge, United States +2
Employees 32
Industries Health Care
Funding Stage Series B
Social

Get notified when Eccogene moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Eccogene recently secured CNY180M in Series B funding, signaling strong investor confidence in its pipeline of small molecule therapeutics for cardiometabolic conditions. A significant future milestone is the planned presentation of Phase 1b data for its lead oral GLP-1 receptor agonist, ECC5004 (licensed to AstraZeneca), at a major conference in June 2026. This highlights the company's continued clinical progress and strategic validation through a major pharmaceutical partnership in a high-demand therapeutic area.

Signal Types
Funding Product Development Partnership
Strategic Labels
Clinical Development Strategic Partnership Pipeline Advancement
Next Move: Clinical Trials
·
Impact: 8/10
·
Ideal For: Biopharma VCs — Series B, Cardiometabolic Therapeutics Investors

About Eccogene

ECCOGENE 诚益生物

Slogan: Pursue extraordinary innovation for a healthier life

Description: Eccogene is a biopharmaceutical company founded in 2018 with a dedication to providing innovative therapeutic solutions for unmet medical needs globally. The company's focus lies in the discovery and development of translational medicine for metabolic and immune-related diseases. Eccogene's expertise in disease biology, medicinal chemistry, and translational science drives the advancement of its novel and differentiated pipeline of drugs.

Industries: Health Care

Headquarter: China

Last Investment: CNY180.00M Series B investment at 12 June 2023

Last Investment Investors: New Alliance Capital, Qingsong Fund, Delos Capital, Acusea/Huiyuan Capital, Yufu Capital, Elikon Venture, Shanghai Zhangjiang Haocheng Venture Capital, Oriza Seed Capital (Oriza Yuandian)

Taxonomy: biopharmaceutical, therapeutic solutions, translational medicine, metabolic diseases, immune-related diseases, disease biology, medicinal chemistry, translational science, drug development, pipeline development

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 9
Investor Investor Investor Investor
•••• •••• 		12 Jun 2023
Series A •••••• 1
Investor
06 Sep 2018

Eccogene Alternatives & Competitors

Eccogene vs
Viking Therapeutics, Inc.
Viking Therapeutics, Inc. United States

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development o...

Post Ipo Equity
59 employees
Health Care, Health and Wellness
Compare Eccogene vs Viking Therapeutics, Inc.
Eccogene vs
Biomea Fusion
Biomea Fusion United States

We are creating an entirely new Generation of Precision Medicine against Genetically Defined Disease...

Post Ipo Equity
99 employees
Biotechnology, Health and Wellness
Compare Eccogene vs Biomea Fusion
Eccogene vs
INVENT Pharmaceuticals
INVENT Pharmaceuticals United States

Transforming molecules to medicines

1 employees
Biotechnology, Health Care
Also compare with: Eccogene vs Vigil Neuroscience Vigil Neuroscience

FAQ About Eccogene

Unlocking the full potential of GLP-1-based therapy
Eccogene was founded in 2018.
Eccogene is headquartered in Cambridge, United States.
Eccogene operates in the following industries: Health Care.
Eccogene has approximately 32 employees.
Eccogene has completed 2 funding rounds, raising a total of $194.63M. The latest funding stage is Series B.
Top alternatives and competitors to Eccogene include Viking Therapeutics, Inc., Biomea Fusion, INVENT Pharmaceuticals, Vigil Neuroscience, Longboard Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Eccogene and Viking Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Eccogene and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy